New antibody shows promise for painful blistering skin disease
NCT ID NCT04563923
Summary
This study tested whether adding avdoralimab, an experimental antibody drug, to standard steroid creams could better control bullous pemphigoid, a painful blistering skin condition that mainly affects older adults. Fifteen hospitalized patients with confirmed bullous pemphigoid participated in this French trial. Researchers compared the combination treatment to steroid creams alone to see which helped patients achieve complete skin healing faster and for longer periods.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM, Hôpital Nord
Marseille, Bouches du rhône, 13000, France
-
APHM, Timone
Marseille, Bouche Du Rhône, 13005, France
-
CHU Montpellier, Dermatologie
Montpellier, Herault, 34005, France
-
CHU de Nice- Dermatologie
Nice, Alpes-Maritimes, 06200, France
Conditions
Explore the condition pages connected to this study.